Last reviewed · How we verify
Hecolin
At a glance
| Generic name | Hecolin |
|---|---|
| Also known as | HEV 239 |
| Sponsor | Xiamen Innovax Biotech Co., Ltd |
| Modality | Biologic |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Immunogenicity and Safety of Hecolin® in HIV Positive/Negative Adults and in Children (PHASE2)
- Safety and Immunogenicity of Hecolin® in Healthy Pregnant Women (PHASE2)
- Effectiveness Trial to Evaluate Protection of Pregnant Women by Hepatitis E Vaccine in Bangladesh. (PHASE4)
- Immunogenicity Study of the Recombinant Human Papillomavirus Virus Type 6/11 Bivalent Vaccine (PHASE2)
- Immunogenicity and Safety of Co-immunization With Cecolin and Hecolin (PHASE4)
- Safety Study of Hepatitis E Vaccine (HEV239) (PHASE1)
- Clinical Trial of Recombinant Hepatitis E Vaccine (PHASE3)
- A Phase Ⅳ Clinical Trial of the Recombinant Hepatitis E Vaccine (Escherichia Coli)(the Lot Consistency Trial) (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Hecolin CI brief — competitive landscape report
- Hecolin updates RSS · CI watch RSS
- Xiamen Innovax Biotech Co., Ltd portfolio CI